Lyell Immunopharma (NASDAQ:LYEL) Trading Up 5.8%

Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) were up 5.8% during mid-day trading on Monday . The company traded as high as $2.36 and last traded at $2.36. Approximately 234,559 shares traded hands during trading, a decline of 77% from the average daily volume of 1,004,176 shares. The stock had previously closed at $2.23.

Analyst Ratings Changes

Separately, HC Wainwright dropped their price objective on shares of Lyell Immunopharma from $8.00 to $6.00 and set a “buy” rating for the company in a research note on Thursday, February 29th.

Lyell Immunopharma Trading Up 1.2 %

The business has a 50-day moving average of $2.31 and a two-hundred day moving average of $2.03.

Lyell Immunopharma (NASDAQ:LYEL) last released its quarterly earnings results on Wednesday, February 28th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.01. The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $4.96 million. Lyell Immunopharma had a negative net margin of 180,486.14% and a negative return on equity of 32.67%. On average, analysts forecast that Lyell Immunopharma, Inc. will post -0.81 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lyell Immunopharma

Several large investors have recently modified their holdings of the company. Invenomic Capital Management LP acquired a new position in Lyell Immunopharma in the fourth quarter valued at approximately $1,448,000. RPO LLC bought a new stake in shares of Lyell Immunopharma in the 4th quarter valued at $38,000. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Lyell Immunopharma during the 4th quarter valued at $31,000. WuXi AppTec Co. Ltd. bought a new position in Lyell Immunopharma during the fourth quarter worth $15,871,000. Finally, Simplicity Solutions LLC bought a new position in Lyell Immunopharma during the fourth quarter worth $93,000. 66.05% of the stock is currently owned by institutional investors and hedge funds.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.